Weight Loss Therapies
4 articles on Weight Loss Therapies, written by Shotlee and medically reviewed for clinical accuracy.
Ozempic and GLP-1 Drugs: Heart Benefits and Personal Realities
Thirty million Americans—one in eight—are turning to GLP-1 drugs like Ozempic for weight management and more, with data showing a 20% reduced risk of heart attacks and strokes. But what happens when the weight doesn't budge, as in 10% of users? This personal story explores the hype, realities, and broader implications of these medications.
4 min read
Genes That Make GLP-1 Drugs Work (or Not): New Study
Why do some people lose remarkable weight on Ozempic while others see minimal results or severe nausea? A new Nature study of nearly 28,000 GLP-1 drug users shows your genes are a key factor. Specific variants in GLP1R and GIPR genes predict both efficacy and side effects, opening doors to personalized prescribing.
5 min read
Python Blood Compound pTOS Could Lead to New Weight Loss Therapies
Researchers at the University of Colorado Boulder have identified para-tyramine-O-sulfate (pTOS) in python blood, a compound that skyrockets after meals to suppress appetite and support metabolic health. Unlike GLP-1 drugs like Ozempic, pTOS drove weight loss in mice without gastrointestinal issues or muscle wasting. This breakthrough, published in Nature Metabolism, hints at new therapies inspired by python metabolism.
5 min read
Eli Lilly Grabs Biggest Slice of GLP-1 Gold Rush Over Ozempic
Eli Lilly has overtaken Novo Nordisk in the GLP-1 gold rush, with Mounjaro and Zepbound now holding 60% of the U.S. market versus Ozempic and Wegovy's 39%. Backed by blockbuster revenue growth and superior weight loss results in head-to-head studies, Lilly's tirzepatide drugs are reshaping obesity and diabetes treatment. Investors and patients alike are taking notice of this shift.
5 min read